Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 76.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 124,875 shares of the biotechnology company’s stock after selling 401,900 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.08% of Ironwood Pharmaceuticals worth $164,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IRWD. Merit Financial Group LLC increased its stake in Ironwood Pharmaceuticals by 17.4% in the 3rd quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 7,232 shares during the period. R Squared Ltd increased its stake in shares of Ironwood Pharmaceuticals by 286.5% during the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 28,735 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Ironwood Pharmaceuticals by 23.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 28,928 shares in the last quarter. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 284.6% in the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in Ironwood Pharmaceuticals in the second quarter valued at about $25,000.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on IRWD shares. Craig Hallum upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Citizens Jmp raised Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price objective on the stock in a report on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.68.

Ironwood Pharmaceuticals Stock Down 6.3%

Ironwood Pharmaceuticals stock opened at $4.49 on Thursday. The firm has a market capitalization of $730.43 million, a PE ratio of 28.06 and a beta of 0.17. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.53 and a 52 week high of $5.78. The firm’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $2.42.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million during the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. On average, research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.